Evotec signs on Merck Group to target discovery platform with CRISPR deal

By Dani Bancroft contact

- Last updated on GMT

Source: Merck KGaA
Source: Merck KGaA

Related tags: Stem cell, Cell biology

Merck KGaA has partnered up with clinical research organisation (CRO) Evotec Ag to serve as a one-stop shop for new target discovery using its gene-editing reagents.

The Merck Group’s Cell Design Studio has been developing cell lines for drug discovery for the past 10 years, but moved to partner with the German CRO.

The deal is to provide new drug discovery programmes using Evotec’s screening platforms and indication expertise – including its previous experience​ with the CRISPR-Cas9 gene-editing technology.

Merck originally acquired​ patents for genetic reagents – including shRNA and viral CRISPR libraries - for gene-editing when it bought Sigma-Aldrich last year.

Evotec will leverage these reagents in its induced pluripotent stem cell (iPSC) platforms to hunt for new drug targets.

COO of Evotec – Mario Polywka – said in a statement “Deploying Merck's assay-ready reagents on our cellular screening platforms and in vivo models creates powerful capabilities in the area of target ID.”

Financials were not disclosed.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related product

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers